Anticancer activity of sodium stibogluconate in synergy with IFNs

Journal of Immunology

Volumn 169, Issue 10, 2002, Pages 5978-5985

  Yi, Taolin ^a   Pathak, Manas K ^a   Lindner, Daniel J ^a   Ketterer, Michael E ^a   Farver, Carol ^a   Borden, Ernest C ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CELL PROTEIN; META TYROSINE; PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; STAT1 PROTEIN; STIBOGLUCONATE SODIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CHROMATOGRAPHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME INACTIVATION; HUMAN; HUMAN CELL; MELANOMA; MOUSE; NONHUMAN; NUDE MOUSE; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN TARGETING; TOXICITY;

EID: 0037111446     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.169.10.5978     Document Type: Article

References (38)

1. Goldman, J. M., and J. V. Melo. 2001. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344:1084.
2. Berman, J., and T. J. O'Leary. 2001. Gastrointestinal stromal tumor workshop. Hum. Pathol. 32:578.
3. Burke, T., Jr., and Z. Y. Zhang. 1998. Protein-tyrosine phosphatases: Structure, mechanism, and inhibitor discovery. Biopolymers 47:225.
4. Berman, J. D. 1988. Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies. Rev. Infect. Dis. 10:560.
5. Pathak, M. K., and T. Yi. 2001. Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines. J. Immunol. 167:3391.
6. Herwaldt, B. L., and J. D. Berman. 1992. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am. J. Trop. Med. Hyg. 46:296.
7. Zhang, J., A. K. Somani, and K. A. Siminovitch. 1999. Roles of the SHP-1 tyrosine phosphatase in the negative regulation of cell signalling. Semin. Immunol. 12:361.
8. Ihle, J. N., W. Thierfelder, S. Teglund, D. Stravapodis, D. Wang, J. Feng, and E. Parganas. 1998. Signaling by the cytokine receptor superfamily. Ann. N Y Acad. Sci. 865:1.
9. Berman, J. D., and D. J. Wyler. 1980. An in vitro model for investigation of chemotherapeutic agents in leishmaniasis. J. Infect. Dis. 142:83.
10. Murray, H. W., and S. Delph-Etienne. 2000. Roles of endogenous γ interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis. Infect. Immun. 68:288.
11. Alexander, J., K. C. Carter, N. Al-Fasi, A. Satoskar, and F. Brombacher. 2000. Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis. Eur. J. Immunol. 30:2935.
12. Murray, H. W., C. Montelibano, R. Peterson, and J. P. Sypek. 2000. Interleukin-12 regulates the response to chemotherapy in experimental visceral leishmaniasis. J. Infect. Dis. 182:1497.
13. Squires, K. E., R. D. Schreiber, M. J. McElrath, B. Y. Rubin, S. L. Anderson, and H. W. Murray. 1989. Experimental visceral leishmaniasis: Role of endogenous IFN-γ in host defense and tissue granulomatous response. J. Immunol. 143:4244.
14. Stark, G. R. 1997. Genetic analysis of interferon and other mammalian signaling pathways. Harvey Lect. 93:1.
15. Vestal, D. J., T. Yi, and E. C. Borden. 2001. Pharmacology of interferons: Induced proteins cell activation and antitumor activity. In Cancer Chemotherapy Biotherapy, 3rd Ed. B. A. Chabner and D. L. Longo, eds. Lippincott Williams & Wilkins, Philadelphia, p. 752.
16. Borden, E. C., D. Lindner, R. Dreicer, M. Hussein, and D. Peereboom. 2000. Second-generation interferons for cancer: Clinical targets. Semin. Cancer Biol. 10:125.
17. Meurs, E., and A. G. Hovanessian. 1988. α-Interferon inhibits the expression of heavy chain μ messenger RNA in Daudi cells. EMBO J. 7:1689.
18. Forsberg, K., I. Valyi-Nagy, C. H. Heldin, M. Herlyn, and B. Westermark. 1993. Platelet-derived growth factor (PDGF) in oncogenesis: Development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGFBB. Proc. Natl. Acad. Sci. USA 90:393.
19. Mickey, D. D., K. R. Stone, H. Wunderli, G. H. Mickey, R. T. Vollmer, and D. F. Paulson. 1977. Heterotransplantation of a human prostatic adenocarcinoma cell line in nude mice. Cancer Res. 37:4049.
20. Cailleau, R., R. Young, M. Olive, and W. Reeves, Jr. 1974. Breast tumor cell lines from pleural effusions. J. Natl. Cancer Inst. 53:661.
21. Matin, S. F., R. R. Rackley, P. C. Sadhukhan, M. S. Kim, A. C. Novick, and S. K. Bandyopadhyay. 2001. Impaired α-interferon signaling in transitional cell carcinoma: Lack of p48 expression in 5637 cells. Cancer Res. 61:2261.
22. Carini, C., B. N. Hudspith, and J. Brostoff. 1981. Effect of prostaglandins and cyclic nucleotides on growth and immunoglobulin secretion of two IgE myeloma cell lines. Br. J. Cancer 43:257.
23. Leibovitz, A., J. C. Stinson, W. R. McCombs. C. E. McCoy, K. C. Mazur, and N. D. Mabry. 1976. Classification of human colorectal adenocarcinoma cell lines. Cancer Res. 36:4562.
24. Lindner, D. J., E. C. Borden, and D. V. Kalvakolanu. 1997. Synergistic antitumor effects of a combination of interferons and retinoic acid on human tumor cells in vitro and in vivo. Clin. Cancer Res. 3:931.
25. Murray, H. W., J. D. Berman, and S. D. Wright. 1988. Immunochemotherapy for intracellular Leishmania donovani infection: γ interferon plus pentavalent antimony. J. Infect. Dis. 157:973.
26. Chou, T. C., and P. Talalay. 1984. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:27.
27. Chawla-Sarkar, M., D. W. Leaman, B. S. Jacobs, R. J. Tuthill, M. Chatterjee-Kishore, G. R. Stark, and E. C. Borden. Resistance to interferons in melanoma cells does not correlate with the expression or activation of signal transducer and activator of transcription 1 (stat1). J Interferon Cytokine Res. 22:603.
28. David, M., H. E. Chen, S. Goelz, A. C. Lamer, and B. G. Neel. 1995. Differential regulation of the α/β interferon-stimulated Jak/Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1. Mol. Cell. Biol. 15:7050.
29. Borden, E. C. 2000. Reducing primary melanoma mortality. Curr. Oncol. Rep. 2:289.
30. You, M., D. H. Yu, and G. S. Feng. 1999. SHP-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway. Mol. Cell. Biol. 19:2416.
31. Yi, T. L., J. L. Cleveland, and J. N. Ihle. 1992. Protein tyrosine phosphatase containing SH2 domains: Characterization, preferential expression in hematopoietic cells, and localization to human chromosome 12p12-p13. Mol. Cell. Biol. 12:836.
32. Adachi, M., E. H. Fishcher, J. Ihle, K. Imai, F. Jirik, B. Neel, T. Pawson, S. Shen, M. Thomas, A. Ullrich, and Z. Zhao. 1996. Mammalian SH2-containing protein tyrosine phosphatases. Cell 85:15.
33. Berman, J. D., and M. Grogl. 1988. Leishmania mexicana: Chemistry and biochemistry of sodium stibogluconate (Pentostam). Exp. Parasitol. 67:96.
34. Hooft van Huijsduijnen, R. 1998. Protein tyrosine phosphatases: Counting the trees in the forest. Gene 225:1.
35. Rice, G. P., J. Oger, P. Duquette, G. S. Francis, M. Belanger, S. Laplante, and J. F. Grenier. 1999. Treatment with interferon β-1b improves quality of life in multiple sclerosis. Can. J. Neurol. Sci. 26:276.
36. Platanias, L. C., and E. N. Fish. 1999. Signaling pathways activated by interferons. Exp. Hematol. 27:1583.
37. Pallen, C. J. 1993. The receptor-like protein tyrosine phosphatase α: A role in cell proliferation and oncogenesis. Semin. Cell. Biol. 4:403.
38. Diamond, R. H., D. E. Cressman, T. M. Laz, C. S. Abrams, and R. Taub. 1994. PRL-1, a unique nuclear protein tyrosine phosphatase, affects cell growth. Mol. Cell. Biol. 14:3752.